Tenax Therapeutics, Inc. (TENX) - 10-K Summary
Business Context and Reporting Period
Company: Tenax Therapeutics, Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2024
Business Overview: Tenax is a clinical-stage pharmaceutical company developing novel cardiopulmonary therapies. The company focuses on repurposing approved drugs for new indications, specifically targeting pulmonary hypertension. Its prioritized product candidate is oral levosimendan (TNX-103) for Pulmonary Hypertension in Heart Failure with Preserved Ejection Fraction (PH-HFpEF). A second candidate, imatinib (TNX-201) for Pulmonary Arterial Hypertension (PAH), has been deprioritized pending the success of the levosimendan program.
Key Financial Metrics
| Metric (in thousands) | 2024 | 2023 |
|---|---|---|
| Revenue | $0 | $0 |
| Total Operating Expenses | $19,494 | $8,234 |
| Net Loss | $(17,602) | $(7,711) |
| Cash and Cash Equivalents (Year End) | $94,851 | $9,792 |
| Working Capital | $92,000 | $8,100 |
| Accumulated Deficit | $(314,855) | $(297,253) |
Debt: The company had no outstanding debt as of December 31, 2024, having repaid a $501,000 note payable used for insurance financing during the third quarter of 2024.
Material Changes vs. Prior Period
- Operating Expenses: Increased 137% to $19.5 million from $8.2 million. This was driven primarily by a 294% increase in Research and Development (R&D) expenses ($12.7 million vs. $3.2 million) due to the initiation of the Phase 3 LEVEL trial for oral levosimendan.
- Liquidity: Cash and cash equivalents surged from $9.8 million to $94.9 million. This increase was fueled by significant financing activities, including a $99.7 million gross proceeds private placement in August 2024 and a $9.0 million registered public offering in February 2024.
- Net Loss: Widened to $17.6 million from $7.7 million, reflecting the ramp-up in clinical trial costs, partially offset by increased interest income ($1.9 million vs. $0.5 million) due to higher cash balances.
Guidance, Outlook, and Risks
Outlook and Capital Resources: Management believes current resources, combined with a subsequent $25.0 million private placement closed in March 2025, are sufficient to fund operations through at least 2027. The company intends to use proceeds to complete the Phase 3 LEVEL study and initiate a second global Phase 3 study (LEVEL-2) for oral levosimendan.
Key Risks:
- Clinical Trial Uncertainty: Success depends on the outcomes of the LEVEL and LEVEL-2 trials. Delays in enrollment or negative results could materially harm the business.
- Need for Additional Capital: The company has no approved products and expects to incur losses for the foreseeable future. Future funding requirements depend on trial progress and regulatory approvals.
- Third-Party Dependence: Tenax relies on Orion Corporation as the sole manufacturer for oral levosimendan and third-party CROs for clinical trials.
- Intellectual Property: The company relies on a license agreement with Orion Corporation, which includes milestone payments (up to $45 million in commercialization milestones) and tiered royalties upon approval and sales.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $94.9 million year-end cash balance plus the $25.0 million March 2025 proceeds to cover the full cost of the LEVEL-2 trial and potential regulatory filing costs.
- Orion License Terms: Review the specific milestone triggers and royalty rates in the license agreement with Orion Corporation, particularly the $10 million FDA approval milestone and the 2030 termination clause.
- LEVEL Trial Enrollment: Monitor the rate of patient enrollment in the Phase 3 LEVEL study, as delays are a primary risk factor cited in the filing.
- Dilution Impact: Assess the impact of outstanding warrants (approx. 19.9 million shares) and pre-funded warrants (approx. 31.9 million shares) on future share count and ownership dilution.
- Imatinib Status: Confirm the strategic decision to deprioritize the imatinib Phase 3 trial and whether resources will be reallocated solely to levosimendan.